Sienna Biopharmaceuticals, Inc. (SNNAQ)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Mar 27, 2025, 4:00 PM EST
Market Cap 23.00
Revenue (ttm) n/a
Net Income (ttm) -47.95M
Shares Out 22.78M
EPS (ttm) -1.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,600
Average Volume n/a
Open n/a
Previous Close 0.0001
Day's Range n/a
52-Week Range n/a
Beta 70.18
RSI 0.02
Earnings Date n/a

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company’s lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trial... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 13
Stock Exchange OTCMKTS
Ticker Symbol SNNAQ
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.